Stanford administers first commercial Orca-T treatment

Stanford says it administered the first commercial Orca-T infusion after the cell therapy received FDA approval in June. The donor-cell treatment aims to reduce graft-versus-host disease following transplantation. This is a move into routine care, according to Stanford; the first recipient’s longer-term outcome was not reported.